Department of Neurological Sciences, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE, USA.
Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12593-12608. doi: 10.26355/eurrev_202012_24057.
The coronavirus disease 2019 (COVID-19) is declared as an international emergency in 2020. Its prevalence and fatality rate are rapidly increasing but the medication options are still limited for this perilous disease. The emergent outbreak of COVID-19 triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) keeps propagating globally. The present scenario has emphasized the requirement for therapeutic opportunities to relive and overcome this latest pandemic. Despite the fact, the deteriorating developments of COVID-19, there is no drug certified to have considerable effects in the medical treatment for COVID-19 patients. The COVID-19 pandemic requests for the rapid testing of new treatment approaches. Based on the evidence, hydroxychloroquine is the first medicine opted for the treatment of disease. Umifenovir, remdesivir, and fevipiravir are deemed the most hopeful antiviral agent by improving the health of infected patients. The dexamethasone is a first known steroid medicine that can save the lives of seriously ill patients, and it is shown in a randomized clinical trial by the United Kingdom that it reduced the death rate in COVID-19 patients. The current review recapitulates the existing evidence of possible therapeutic drugs, peptides, humanized antibodies, convulsant plasma, and vaccination that has revealed potential in fighting COVID-19 infections. Many randomized and controlled clinical trials are taking place to further validate these agent's safety and effectiveness in curing COVID-19.
2020 年,新型冠状病毒病(COVID-19)被宣布为国际紧急事件。其发病率和死亡率迅速上升,但针对这种危险疾病的药物选择仍然有限。由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引发的 COVID-19 紧急爆发在全球范围内不断传播。目前的情况强调了需要治疗机会来缓解和克服这一最新的大流行。尽管 COVID-19 的恶化发展,没有一种药物被证明对 COVID-19 患者的治疗有显著效果。COVID-19 大流行要求快速测试新的治疗方法。基于证据,羟氯喹是第一种用于治疗疾病的药物。乌米非韦、瑞德西韦和法匹拉韦被认为是最有希望的抗病毒药物,能改善感染患者的健康状况。地塞米松是第一种已知的可挽救重症患者生命的类固醇药物,英国的一项随机临床试验表明,它降低了 COVID-19 患者的死亡率。本综述回顾了可能的治疗药物、肽、人源化抗体、抗惊厥血浆和疫苗的现有证据,这些证据显示了它们在对抗 COVID-19 感染方面的潜力。许多随机对照临床试验正在进行,以进一步验证这些药物在治疗 COVID-19 方面的安全性和有效性。